Summary

Results from the Randomized Evaluation of Long-Term Anticoagulant Therapy [RE-LY] trial showed that the oral direct thrombin inhibitor dabigatran is a safe and effective alternative to warfarin for the prevention of stroke in patients with atrial fibrillation.

  • Cardiology Clinical Trials
  • Arrhythmias
  • Cerebrovascular Disease
View Full Text